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The Lewis Blood Group System in Liver Transplantation 
G. Ramsey, J. Wolford, D.J. Boczkowski, F.W. Cornell, P.larson, and T.E. Starzl 
THE LEWIS blood group antigens Lea and Leb have been found on red blood cells 
(RBCs), in secretions and fluids such as sali-
va, alimentary tract juice, and urine, and in 
various tissues including renal tubular cells, 
collecting ducts, urothelium, and ductal or 
mucosal epithelium of the sweat glands, sali-
vary glands, gastrointestinal tract, pancreas, 
uterus, cervix, and breast. l .s Hepatic bile duct 
epithelium also contains Lewis antigens.9 
Lewis antigens in secretions are glycoproteins. 
RBC Lewis antigens are glycolipids acquired 
from plasma and are not intrinsic to the 
RBCs.6,lo Transfused RBCs have been found 
to assume the recipient's Lewis phenotype by 
absorption or loss of antigens within two to 
seven days,B.12 and bone marrow transplant 
patients retain their own RBC Lewis pheno-
type, not that of their donors. 13,14 The site of 
origin of Lewis plasma glycolipids is uncer-
tain. Evans et aI's proposed the small intestine 
as a possible source. Crookstonl6 suggested 
that the study of RBC Lewis phenotypes in 
liver transplants would shed light on this 
issue. 
Lewis antibodies are generally clinically 
insignificant in RBC compatibility, in part 
because of the shift of transfused RBCs to the 
recipient's phenotype. 12 However, in renal 
transplantation, Lewis incompatibility has 
been reported to adversely affect graft surviv-
al. l7•l9 Some Lewis antibodies are lymphocy-
totoxicl9 and others are not detected by rou-
tine hemagglutination techniques. IS In one 
case an anti-host Lewis antibody of bone 
marrow graft origin was associated with renal 
failure in the recipient.20 However, other clini-
cal studies have not found a significant 
adverse effect of Lewis incompatibility in 
renal transplantation.21.23 
On a random basis by prediction from 
Lewis phenotype frequencies,24 an estimated 
20% of whites and 35% of blacks getting 
transplants from unrelated donors receive 
Lewis-incompatible organs. These figures are 
derived from the sum of approximately 5% of 
whites and 20% of blacks who are Le(a- b-) 
and predicted to receive Lewis-positive grafts, 
plus another 15% in each group who are 
Le(a + b -) and predicted to receive 
Le(a-b+) organs. 
We studied Lewis-incompatible liver trans-
plants with regard to the subsequent recipient 
RBC Lewis phenotype and the graft outcome. 
Our goals were twofold: (1) to assess the role 
of the Lewis blood group system in hepatic 
transplant compatibility, and (2) to determine 
whether the liver is the source of RBC Lewis 
antigens. 
MATERIALS AND METHODS 
Patients were studied in the liver transplant program at 
the University of Pittsburgh. Surgical and immunosup-
pressive methods and transfusion practices have been 
described.25-28 Children under 6 years of age were 
excluded in our study because young children do not fully 
express ROC Lewis antigens.12 Patients with mixed pre-
transplant ROC Lewis typings attributed to recent trans-
fusions were excluded from our prospective cases. ROC 
Lewis typings were performed in standard fashion on 
clotted or ethylenediaminetetraacetate (EDT A)-antico-
agulated specimens from the patient prior to transplant 
and from the organ donor when available. Posttransplant 
Lewis typings were done at least II days after the most 
recent RBC transfusion, except in one case (see Results). 
Some posttransplant typings were performed on heparin-
ized specimens sent for cycJosporine levels and kindly 
provided by Howard Seltman. Patient 2's posttransplant 
Lewis typing was kindly arranged by Arthur S. Lebowitz 
and the New York University Medical Center blood 
bank. We performed the secretor study with saliva using 
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hemagglutination inhibition.24 Patient followup was 
included through January 1, 1987. 
RESULTS 
Seventeen definite or probable Lewis-
incompatible liver transplants were studied in 
12 patients (Table 1). Patients 1 through 3 
were identified retrospectively because of hav-
ing had Lewis antibodies; the others were 
found in a prospective search for Le(a- b-) 
or Le(a + b-) recipients. Ten Le(a- b-) 
patients received 15 grafts. RBC Lewis typ-
ings were done on four of these organ donors; 
the other 11 were most likely Lewis incompat-
ible because only 6% of whites and 22% of 
blacks are Le(a-b- ).24 Two Le(a+b-) 
patients (cases 7 and 9) received Le(a-b+) 
livers. 
Excluding graft 11 C, for which only 1 
month's follow-up has elapsed, 9 of the 16 
grafts (56%) in Table 1 were surviving at 7 to 
44 months. This rate is comparable to our 
center's overall 6-month actuarial survival of 
58% for all hepatic grafts.29 Two patients were 
retransplanted after rejection (graft 6A, 
which also had arterial thrombosis present, 
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and grafts llA and lIB); their current grafts 
were surviving at 13 months and 1 month. Ten 
of these 12 patients (84%) were surviving ~ 7 
months after transplant, compared to our pro-
gram's overall 6-month actuarial patient sur-
vival rate of 73%.29 The two deaths were not 
related to rejection. Thus, the presence of 
Lewis incompatibility did not adversely affect 
overall patient or graft survival. 
In 13 of the 17 transplants, RBC Lewis 
typing was performed after the transplant. 
The interval from transplant to typing is 
shown in Table 1. Patient 1 is presumed to be 
originally Le(a- b-) because of the presence 
of anti-LebH before graft B (see below). All 
posttransplant typings shown were done ~ 11 
days after the most recent RBC transfusion, 
except in case 12B, in which repeated transfu-
sions were needed and the Le( a - b -) typing 
was obtained 6 days after 2 units of RBCs. All 
retained their original Lewis RBC phenotype 
except for patient 4, whose RBCs were 
Le(a-b+) 3 weeks and 8 months posttrans-
plant; her saliva also contained Leb in a 
secretor study at 3 weeks. Postoperative RBC 
specimens were not obtained after transplants 
Table 1. RBC Lewis Phenotypes and Outcomes of 17 Definite or Probable Lewis-Incompatible Liver Transplants 
RBC Phenotype 
Recipient 
Patient-Graft Disease Donor Preop Postop Graft Survival 
1A CAH NT NT Lea - b-, 11 d 11 d, arterial thrombosis 
1B NT Le,-b- NT 44mo+ 
2 NANBH NT Lea - b - Lea- b-, 22 mo 41 mo+ 
3 Alagille's NT Lea- b- Le,-b-, 16 d 20mo+ 
4 Wilson's NT Lea - b- Lea - b+, 21 d + 8 mo 16 mo+ 
5 CAH NT Lea - b- Lea - b-, 7 mo 14mo+ 
6A CAH NT Lea - b- Lea- b-, 16 d 1 mo, rejection + arterial thrombosis 
6B NT Lea- b- Lea - b-, 6 mo 13mo+ 
7 CAH Le8 - b + Lea+b - NT 13mo+ 
8 CAH Lea - b + Lea- b - Lea - b -, 1 mo 10 mo+ 
9 CIR Lea- b+ Le8 +b- Le8 +b -. 1 ma 7mo+ 
10 PBC NT Lea- b- Lea- b-, 15 d 5 mo, died, Pneumocystis pneumonia 
11A PBC Lea - b+ Lea- b - Le,-b-, 7 wk 4 mo, chronic rejection 
11B NT Lea - b- NT 4 mo, acute rejection 
11C NT NT Le'-b-, 25 d 1 mo+ 
12A CHF Le8 - b + Lea - b - NT 1 wk, harvest ischemia 
12B Lea+b- NT Le'-b-, 23 d 1 mo, died, stroke 
Abbreviations: CAH, chronic active hepatitis; NT, not tested; NANBH, non-A, non-B hepatitis; CIR, cirrhosis; PBC, primary 
biliary cirrhosis; CHF, congenital hepatic fibrosis. 
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1 B, 7, and 11 B, and were not done after case 
12A because of retransplantation 1 week after 
the transfusions with graft 12A. 
The postoperative typings in Table 1 were 
the initial ones performed, except in patients 5 
and 8 where transfused Le(b+) RBCs were 
still detected at 17 days in each case. This 
interval was somewhat longer than in other 
reports. II ,12 These two patients received 13 
and 18 units of RBCs at transplant, respec-
tively. The other six patients who were 
retyped from 11 days to 1 month after trans-
plant, and who retained their original Lewis 
phenotype, received from 3 to 11 units of 
RBCs (cases 3, 6A, 8, 9, ltC, and 12B). All of 
these patients received intraoperative fresh 
frozen plasma (FFP) on a one-for-one basis 
with RBCs,21,28 and plasma transfusion is also 
a source of Lewis antigens.12 Thus, transfu-
sions of up to 11 units of RBCs and FFP at the 
time of transplant did not affect results of 
postoperative RBC Lewis phenotyping 11 
days to 1 month later. 
Ten control patients receiving Lewis-com-
patible livers also had postoperative RBC 
Lewis phenotypings. Nine were Le(a-b+) 
patients whose donors were Le(a- b+) (3), 
Le(a+ b-) (2), or unknown (3), and one was 
Le(a+b-) with an Le(a+b-) liver. 
Le(a- b+) subjects are compatible with 
Le( a + b - ) blood or tissue, and do not make 
anti-Lea, because Lea is the precursor for Leb 
and Le(a-b+) subjects have small amounts 
of circulating Lea. All of these ten patients 
retained their original Lewis phenotype. 
Three patients had pretransplant serum 
Lewis antibodies. Anti-LebH, which reacts 
most strongly with group 0 and A2 Le(b+) 
RBCs having abundant H substance, was 
detected prior to grafts 1 Band 2. Patient 2 
was group B and received a group 0 liver 
(high H content). She subsequently developed 
anti-B from graft lymphocytes and in that 
context was reported previously by Ramsey et 
al30 (patient 2 of that series). Patient 3 had 
preoperative serum anti-Lea and anti-Leb 
reacting weakly to enzyme-treated RBCs in 
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indirect antiglobulin testing. At 16 days after 
surgery, the strength of the anti-Leb had 
increased to 3 + while the anti-Lea was 
unchanged. Despite these preoperative Lewis 
antibodies, all three of these grafts are surviv-
ing. 
DISCUSSION 
In our study, Lewis incompatibility did not 
result in increased graft loss. Six-month graft 
survival in our 17 definite or probable Lewis-
incompatible grafts was 56%, compared to 
58% in our program's overall experience.29 
Liver transplants are also relatively more tol-
erant of ABO and HLA mismatching than 
renal grafts. Although ABO compatibility is 
sought whenever possible, a number of suc-
cessful ABO-incompatible liver transplants 
have been performed in our program.29 Also, 
hepatic grafts are performed without regard 
for HLA matching or lymphocytotoxicity 
crossmatching.31 In contrast, renal transplants 
frequently undergo hyperacute rejection in 
ABO incompatibility, are adversely affected 
by HLA mismatching and incompatibility, 
and in some series have had reduced survival 
when Lewis incompatibility is present. Our 
findings with the Lewis blood group system in 
liver transplantation are consistent with the 
generally greater tolerance of the trans-
planted liver for other tissue incompatibili-
ties. 
We have also shown that the liver is gener-
ally not the source of RBC Lewis glycolipids. 
In 12 of 13 definite or probable Lewis-incom-
patible liver transplants, the recipient retained 
his or her original RBC Lewis phenotype. All 
recipients were Le( a - b -) except for two 
Le(a+b-) patients who received Le(a-b+) 
livers. The single apparent RBC phenotype 
switch was in a patient with Wilson's disease 
who appeared to be Le(a-b-) preoperative-
ly, but Le(a- b+) postoperatively. In retro-
spect in this patient, we cannot rule out the 
possibility of preoperative weakened RBC 
Lewis expression, which has been observed in 
the settings of pregnancy, alcoholic cirrhosis 
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and pancreatitis, and chronic renal fail-
ure. 19,32,33 In contrast to alcoholic cirrhosis, 
Stigendal et al33 found normal expression of 
RBC Lewis antigens in chronic active hepati-
tis and primary biliary cirrhosis. Further stud-
ies would be required to determine whether 
Wilson's disease might be associated with 
reduced RBC Lewis expression in some 
patients. 
Evans et ailS proposed that Lewis antigens 
in the small intestinal lumen are processed by 
the mucosa into small dialyzable forms that 
are then absorbed into the plasma and 
excreted in the urine. However, the material 
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they studied in the small intestine was pre-
sumed to be glycoprotein, not glycolipid as is 
present on RBCs. Our data appear to rule out 
enterohepatic-plasma circulation of RBC 
Lewis antigens. Further information on possi-
ble small intestinal origin of plasma Lewis 
glycolipids could be gleaned from future stud-
ies of small intestinal transplantation.14 We 
have studied an Le(a-b-) patient who 
received a pancreas transplant (unknown 
donor Lewis type), including the spleen and a 
small cuff of duodenum; the patient's RBCs 
were still Le( a - b - ) at 7 weeks, and the graft 
is functioning at 15 months. 
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